NEW Join or new Affiliate program, earn more shopping more!
Third-Party Testing Results
Every batch is independently tested by Janoshik for quality and transparency.
Powered by TESTIDES
VERIFIED
This batch has passed all tests.
High purity and accurate concentration.
Purity
High Purity
Identity
Confirmed
Concentration
Accurate
Compounds
No Harmful Additives
Product Information
Survodutide is an investigational, long-acting peptide designed to activate two receptors involved in metabolic regulation: the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor.
Product
Survodutide
Dosage
10mg
Product Form
Lyophilized Powder
Storage
Refrigerate After Reconstitution
Mechanism of Action
Dual-Receptor Activity
Survodutide is designed to activate two distinct hormonal pathways within a single molecule.
GLP-1 receptor activity influences appetite, satiety and glucose-dependent insulin secretion. Glucagon receptor activity contributes to energy metabolism and may influence liver fat metabolism.
The objective of this dual mechanism is to investigate how coordinated receptor activation may affect body weight and metabolic health.
1. GLP-1 Receptor Activity
GLP-1 is an incretin hormone involved in the body’s response to food intake.
Activation of the GLP-1 receptor can enhance glucose-dependent insulin secretion, reduce inappropriate glucagon release when blood glucose is elevated, delay gastric emptying and influence appetite-related signalling.
These effects may contribute to improved blood glucose control and reduced food intake.
2. Glucagon Receptor Activity
Glucagon plays an important role in regulating energy availability and glucose metabolism. Its actions extend beyond blood glucose regulation to include pathways involved in liver metabolism and energy expenditure.
Survodutide’s glucagon receptor activity is a central feature of its research profile. Scientists are investigating whether this pathway can complement GLP-1 activity to influence energy balance and reduce liver fat.
The combined effect is complex. Glucagon receptor activation can also increase glucose production, so its overall metabolic impact depends on how it interacts with the GLP-1 pathway.
Areas of Clinical Research
Body-Weight Management
Survodutide is being investigated in adults living with overweight or obesity, both with and without type 2 diabetes.
In the phase 3 SYNCHRONIZE-1 trial, published in 2026, participants receiving survodutide experienced average weight reductions of up to 16.6% over 76 weeks under the trial’s efficacy analysis. Outcomes varied according to the treatment group and analysis method.
These findings are clinical-trial results, not a guarantee of individual weight loss or evidence that an unapproved product is safe for self-administration.
Glycemic Control
Researchers are evaluating survodutide in people with type 2 diabetes to assess its effects on blood glucose and glycated haemoglobin (HbA1c), alongside changes in body weight and other metabolic measures.
In the phase 3 SYNCHRONIZE-2 trial, published in October 2026, weight reduction of up to 13.1% was reported under the efficacy analysis over 76 weeks in participants with overweight or obesity and type 2 diabetes.
The findings support continued investigation. They do not establish an approved indication or replace individualized diabetes care.
Liver Health
One of survodutide’s distinctive research areas is metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease characterized by inflammation and liver injury.
Researchers are investigating whether its combined receptor activity can reduce liver fat and improve markers of liver inflammation and fibrosis.
Phase 3 studies are evaluating these outcomes in people with MASH and different stages of liver fibrosis. These findings remain specific to the populations and endpoints studied.
Survodutide Compared With Other Incretin-Based Compounds
| Compound | Primary receptor targets |
|---|---|
| Semaglutide | GLP-1 |
| Tirzepatide | GIP and GLP-1 |
| Retatrutide | GIP, GLP-1 and glucagon |
| Survodutide | GLP-1 and glucagon |
Survodutide differs from tirzepatide by targeting the glucagon receptor rather than the GIP receptor. It differs from retatrutide by targeting two receptors rather than three.
These distinctions describe pharmacology. They do not establish which compound is more effective or safer. Reliable comparisons require appropriately designed clinical trials and consideration of each compound’s regulatory status.
FAQ
Before reconstitution, this product is stable at room temperature for short periods, such as during shipping, but refrigeration is recommended for longer-term storage. After reconstitution, it must be refrigerated. Keep away from direct light. This product is stored refrigerated until it ships.
Peptides are made up of chains of amino acids, and some of those amino acids are hydrophobic — meaning they don’t interact well with water. When a peptide contains a high percentage of these hydrophobic residues, it tends to resist dissolving in water and will aggregate, or clump together. These clumps can then trap water, forming a gel-like or stringy texture rather than dissolving into a nice, smooth solution.
Other contributing factors include:
High peptide concentration – Crowding the solution can push molecules together.
pH and temperature – Solubility can vary depending on how acidic or warm the environment is.
Solvent selection – Some peptides do better with alternatives to bacteriostatic water, such as acetic acid or DMSO.
Reconstitution speed – Adding diluent too quickly can shock the peptide into clumping.
Even if the peptide isn’t highly hydrophobic, under the right (or wrong) circumstances, it can still temporarily behave this way.
While nearly any peptide can gel under the right conditions, some are well-known for their gelling tendencies. Here’s a list of the usual suspects:
AOD-9604
Probably the most infamous of all — AOD tends to form a thick, stringy gel if not handled carefully. This one is very hydrophobic and sensitive to temperature and concentration.
GHK-Cu
Copper-bound peptides like GHK-Cu can form gels or crystals depending on the solvent used and the ambient pH. Copper itself doesn’t help the solubility much.
Thymosin Beta-4 (TB-500)
While this one often dissolves well at lower concentrations, it can develop a gel-like consistency if overdosed into a small volume of liquid.
Melanotan II
Known for being finicky, MT2 can clump or gel, especially if it’s cold when reconstituted or the water is added too quickly.
CJC-1295 (DAC and non-DAC)
This longer peptide sometimes forms viscous solutions, especially when not given time to dissolve fully. It benefits from warm temps and slow mixing.
BPC-157
BPC usually dissolves well, but under some conditions (like high concentration or cold storage), it may start to gel or form strands.
IGF-1 LR3
This is more rare, but at high concentrations or if pH is off, this growth factor can aggregate and become cloudy or sticky.
Epitalon
A short peptide, but still known to occasionally form light gels — especially if the reconstitution environment is less than ideal.
Selank / Semax Variants
These nootropic peptides are usually stable but have been reported to gel when compounded at higher concentrations or exposed to rapid temperature changes.
If you’re dealing with a gelling peptide, here are a few simple tips that can help bring it back into proper solution:
1. Warm the vial gently
Let the vial come to room temperature before reconstituting. If needed, place it in a warm (not hot!) water bath for a few minutes to loosen things up.
2. Add your solvent slowly
Instead of blasting bacteriostatic water into the vial, let it drip slowly down the side. This allows the peptide to dissolve gradually and reduces shock to the material.
3. Swirl, don’t shake
Shaking creates bubbles and doesn’t help dissolve aggregates. A gentle swirl or rolling the vial between your hands is more effective.
4. Let it sit
Sometimes the peptide just needs time. Let it rest after adding solvent, then check back in 10–15 minutes and gently swirl again.
5. Try an alternate solvent
If the peptide still doesn’t dissolve, small amounts of 0.6% acetic acid or even DMSO (for research use only) can help break up stubborn hydrophobic clumps.
6. Dilute further if needed
If you’re working with a very high concentration, it may be helpful to use a larger volume of solvent to encourage full dissolution.
Peptide gelling is not a quality issue, nor is it a manufacturing problem — it’s simply a result of biochemical properties interacting with water and environment. Hydrophobic sequences, high concentrations, or quick handling can all lead to temporary clumping or gel formation.
With a little patience and the right technique, almost all gelling issues can be reversed or avoided. If you work with these peptides regularly, getting familiar with their personalities — and knowing how to coax them into solution — will save you time and frustration.
So next time your peptide gels, just remember: it’s not broken — it’s just being dramatic.
